Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Watchdog U-turn leads to quickfire EMIS profit of 39%

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
EMIS (EMIS:AIM) £19.08
Gain to date: 39%
Readers who backed our recent arbitrage call on EMIS (EMIS:AIM) should be feeling pretty chuffed having banked a rough 39% in five weeks, and we called it spot on.
We said at the time (6 Jul) that this investment pitch was ‘a little different to the sort of investment ideas Shares typically presents to readers,’ but having paid-off much like we said it might, what should shareholders do now?
WHAT HAS HAPPENED SINCE WE SAID TO BUY?
First, let’s recap. NHS technology platform supplier EMIS provides vital technology to the UK’s thousands of GP practices and millions of NHS users. A £1.2 billion takeover offer from US peer UnitedHealth (UNH:NYSE) was agreed more than a year ago, but the deal was put under investigation by the UK’s Competition and Markets Authority.
EMIS is estimated to hold a UK market share of more than 50% in electronic patient records through its EMIS Web platform. The company currently integrates with several third-party systems but doing so in the future could
be seeding business to rivals of Optum, UnitedHealth’s UK arm.
Now the CMA has changed its mind about competition concerns in a late volte-face, largely because it thinks the NHS will be able to use its oversight role to prevent the merged business from harming the competitiveness of rivals.
Megabuyte analyst Ieuan Turner says: ‘Remarkably, no disposals have been deemed necessary as it all stems down to the oversight role that the NHS holds in the UK healthcare market.’
WHAT SHOULD INVESTORS DO NOW?
The CMA will conduct a public consultation on the provisional findings before it releases its final report, scheduled for October 2023, but the stock has surged, to £19.08.
That modest discount to the £19.25 agreed cash takeover price suggests some marginal doubts over the deal remain, although a spanner being thrown into the works looks very unlikely. Still, why take any risk at all?
Shares believes you’re better off closing the trade now, banking your 39% profit (less costs) and moving on to something else.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.
Our website uses cookies to give you a better browsing experience.
You can choose to accept all cookies, or control which we use by clicking 'Manage cookies'. To learn more, read our cookie policy.